
Oxford Nanopore
To enable the analysis of anything, by anyone, anywhere
Glycomine, Inc. is a clinical-stage biotechnology company headquartered in San Carlos, California, that specializes in developing therapeutics for serious rare genetic diseases which currently lack disease-modifying treatment options. Founded in 2014, the company is focused on creating replacement therapies that restore missing biological functions in patients suffering from these rare disorders.
The company’s lead product candidate, GLM101, is a first-in-class mannose-1-phosphate replacement therapy designed to treat phosphomannomutase 2-congenital disorder of glycosylation (PMM2-CDG), a life-threatening rare genetic disease characterized by defective glycosylation. Unlike symptom-only therapies, GLM101 aims to be disease-modifying and is currently undergoing clinical trials including Phase 2b.
Glycomine’s mission is to develop therapeutics for the approximately 7,000 rare disorders worldwide, addressing the unmet medical needs of more than 20 million people affected by rare diseases in the U.S. alone. The company has successfully raised substantial funding, including a $115 million Series C round in April 2025, aimed at advancing its lead program deeper into clinical development.
The company also holds several patents related to rare diseases, autosomal recessive disorders, and protein therapeutics, underscoring its commitment to pioneering treatments in this specialized biotech field. Its approach includes substrate, enzyme, and protein replacement therapies to restore biological functions lost due to rare genetic defects.
With robust financial backing from notable investors like CTI Life Sciences Fund, abrdn Inc., Advent Life Sciences, Novo Holdings, and Sanofi Ventures, Glycomine is well-positioned to advance its therapies and improve patient outcomes for rare genetic disorders.
Report this companyCompany DescriptionGlycomine is a small clinical stage bio tech company committed to developing therapeutics for congenital disorders of glycosylation (CDG), serious rare diseases for which the vast majority of which do not have any disease-modifying treatment options available.Β Many of these diseases are driven by a genetic mutation that disrupts the function of an important enzyme….
Some companies operating in Biotechnology industry.
To enable the analysis of anything, by anyone, anywhere
Transforming Cancer Care with AI Precision Medicine
Worldwide Clinical Trials is the cure for the common CRO, providing top-performing clinical development services globally.
Science for a Safer World.
Guarding the quality of human life from cancer by empowering patients and providers with critical insights for precision oncology.
Engineering a transformative tomorrow
To serve patients.
Committed to developing innovative medicines and partnering with the global community to help as many patients with cancer as possible.
Jobicy
562 subscribers are already enjoying exclusive, experimental and pre-release features.
Free
USD $0/month
For people just getting started
Plus
USD $8/month
Everything in Free, and:
π π
Work at Glycomine? Share your experiences.